DOD Long-Term Survivors of Ovarian Cancer (LTSOC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02321735|
Recruitment Status : Recruiting
First Posted : December 22, 2014
Last Update Posted : March 17, 2016
|Condition or disease||Intervention/treatment|
|Ovarian Cancer||Behavioral: Quality of life questionaire|
Background: Ovarian cancer (OC) remains a major health problem in the United Sates (US). In 2012, there will be an estimated 22,280 cases of epithelial OC (EOC) resulting in 15,500 deaths. While the median survival of OC patients has improved over the last two decades, the vast majority of patients suffer relapse and develop chemo-resistant disease. The overall survival of patients suffering from OC has not changed appreciably over the last three decades. Despite these dismal statistics, there is a minority of OC patients who are long-term (LT) survivors (>10 years). This includes a subset of advanced stage (~15%) and a higher proportion of early-stage disease (75%). Unfortunately, there is little genomic or biologic characterization of these tumors, or patient-reported outcomes that characterize LT survivors. The clinical importance of identifying subsets of patients who may or may not benefit from therapy, and understanding the biology of their tumors, is significant both from a patient survival and quality of life (QOL) standpoint. The characterization of LT survivors of advanced stage OC will potentially identify molecular and clinical pathways that can be targeted to help women who have shorter survivals. Further, careful characterization of these patients, including their initial and longitudinal health-related QOL reports, their response to treatments, and their tumors will provide significant measures of prognostic factors. Accurate identification of women with high-grade, early stage OC who will recur will allow for tailoring therapy to only those who will benefit. Thus, the systematic molecular and patient-reported outcomes evaluation of LT survivors of OC (both early and advanced stage) will yield data, which can significantly impact the management of OC patients.
Overall Aim: To characterize the genomic, biologic, and biobehavioral basis for LT survivors of EOC. We hypothesize that LT survivors of OC have distinct features that distinguish them from short-term (ST) survivors.
- To characterize the genomic, biologic, and immunologic features of tumors from LT versus ST survivors of advanced stage EOC. We propose to evaluate the genomic features (copy number variation, miRNA and methylation patterns) in LT (>7 years) versus ST survivors (<2 years). In addition, all cases will be evaluated for tumor infiltrating lymphocytes (TILs). Correlations between TILs and genomic parameters will be examined along with the identification of genomic/immune signatures that predict for LT survival. This aim leverages ongoing funded projects characterizing the transcriptome of advanced stage OC using GOG trials.
- To validate a genomic signature that predicts for recurrence of early-stage, high-grade EOC. This aim will leverage an ongoing DOD grant (DOD#OC110628; Birrer, PI) generating a genomic signature (transcriptome) that distinguishes recurrent from non-recurrent early-stage, high-grade EOC.
- To determine the extent to which health-related QOL measures, additional patient-reported outcomes (PROs), and key CTCAE criteria predict LT ovarian cancer survival.
- To examine as an exploratory aim, the potential relationship between health-related QOL, PROs, and key CTCAE criteria with genomic features predicting disease recurrence.
Proposed Consortium: We propose utilizing the Gynecologic Oncology Group (GOG) infrastructure as the basis for the consortium, supplemented by the addition of research sites, administrative structure, advisory boards, and biostatistical support. We consider this to be a major advantage for this proposal in that the de novo creation of a consortium will not be necessary. GOG is the world's leading clinical trial organization focused on the prevention, diagnosis, and treatment of gynecologic cancers. GOG includes over 391 medical institutions participating in GOG clinical trials. As such, these institutions are familiar with all GOG procedures including the accurate collection of clinical and QOL data and the procuring and processing of tissue specimens. GOG institutions have extensive infrastructure in place to conduct large-scale clinical research and will serve as an established network of key sites for this project.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Genomic, Epigenomic, and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer - Recruitment|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||September 2019|
Long-Term Ovarian Cancer survivors
Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
Behavioral: Quality of life questionaire
Patients will participate in a QOL questionaire followed by a phone interview
- Quality of life questionnaire [ Time Frame: 5 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02321735
|Contact: Giulia Fulci, PhDfirstname.lastname@example.org|
|Contact: Michael Birrer, MD PhDemail@example.com|
|United States, Massachusetts|
|Massachusetts General Hospital (The General Hospital Corp)||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Giulia Fulci, PhD 617-643-5130 firstname.lastname@example.org|
|Contact: Michael Birrer, MD PhD 6177268624 email@example.com|
|Principal Investigator:||Michael Birrer, MD PhD||MGH|